Cytomegalovirus (CMV) Market: Size, Status, Opportunity Analysis and Forecasts to 2027

A new independent 162 page research with title 'Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte With n-number of tables and figures examining the Cytomegalovirus (CMV) Market, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Request a sample report @ https://www.htfmarketreport.com/sample-report/1378119-cytomegalovirus-cmv-1

Summary
Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027

Cytomegalovirus (CMV) is a β human herpesvirus (HHV-5) of the herpesviridae family. Exposure to the virus can result in lytic infection, producing symptoms that range from those of a common cold to more serious morbidities, including hepatitis and pneumonitis. CMV also has the capacity to establish life-long latent infections, incorporating genomic DNA into host cells without detectable viral gene expression. CMV is a globally ubiquitous pathogen that affects 1/3 of children by the age of 5 and over half of adults by the age of 40. Although largely asymptomatic in immunocompetent adults, CMV infection is a clinically significant disease in patients with compromised immune systems or those receiving immunosuppressive therapy. Particularly vulnerable patients include solid organ transplant (SOT), bone marrow transplant (BMT), hematopoietic stem cell transplant (HSCT), and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) patients, as well as newborns that acquire the infection by transmission from the mother through the placenta.

Currently available therapies for CMV can be divided into two general classes: antiviral drugs for treatment of clinically significant CMV infections and antiviral drugs for CMV prophylaxis. The majority of antivirals are administered in a clinical setting as both therapy and prophylaxis, with variations in dosing parameters depending on the treated patient population. However, major shifts are expected to occur in the CMV market during the forecast period with the projected launch of first-in-class products for CMV therapy and prophylaxis, including cellular immunotherapy and a CMV vaccine.

Key Questions Answered

- How will the CMV therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2017-2027?
- What are the most promising late-stage pipeline drugs for CMV?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
- What are the remaining unmet needs in CMV treatment management?
- What drivers and barriers will affect CMV therapeutics sales in the 7MM over the forecast period?

Scope

- Overview of CMV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline CMV market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting CMV therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global CMV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CMV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CMV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies Mentioned in the Report

Atara Bio
Biotest AG
Helocyte
Merck & Co.
Novartis
Shire
ViraCyte

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/1378119-cytomegalovirus-cmv-1

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Cytomegalovirus (CMV): Executive Summary 8
2.1 Moderate Growth Is Projected for the CMV Market from 2017 to 2027 9
2.2 Manufacturers Are Focusing on Novel CMV Prophylactic Strategies with Less Toxicity 10
2.3 Significant Unmet Need Remains for Products to Prevent Congenital CMV Infections 11
2.4 Opportunities Exist for Long-Term and Cost-Effective Prophylaxis Therapies 11
2.5 Diverse Pipeline Therapies Poised to Begin Addressing Unmet Needs 12
2.6 What Do Physicians Think? 14
3 Introduction 17
3.1 Catalyst 17
3.2 Related Reports 18
3.3 Upcoming Related Reports 18
4 Disease Overview 19
4.1 Etiology and Pathophysiology 19
4.1.1 Etiology 19
4.1.2 Pathophysiology 23
5 Epidemiology 25
5.1 Disease Background 25
5.2 Risk Factors and Comorbidities 25
5.3 Global and Historical Trends 27
5.3.1 CMV Disease in Diagnosed Prevalent HIV Patients 28
5.3.2 CMV Disease in SOT Patients 29
5.3.3 CMV Disease in HSCT Patients 29
5.3.4 Congenital CMV Disease 30
5.4 Forecast Methodology 30
5.4.1 Sources 31
5.4.2 Forecast Assumptions and Methods 35
5.5 Epidemiological Forecast for CMV (2017-2027) 49
5.5.1 Diagnosed Incident Cases of CMV 49
5.5.2 Age-Specific Diagnosed Incident Cases of CMV 50
5.5.3 Sex-Specific Diagnosed Incident Cases of CMV 51
5.5.4 CMV Diagnosed Incident Cases by Populat

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1378119-cytomegalovirus-cmv-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=1378119

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
https://www.linkedin.com/company/13388569/
https://www.facebook.com/htfmarketintelligence/
https://twitter.com/htfmarketreport
https://plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author

This release was published on openPR.